Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Senseonics Holdings, Inc. (SENS) announced the enrollment of its first pediatric participant in the ENHANCE clinical trial for the Eversense® 365-day continuous glucose monitoring (CGM) system. This pivotal trial, directed by Dr. Timothy Bailey at AMCR Institute, aims to evaluate the system's accuracy and safety over one year, with a focus on extending its benefits to young diabetes patients aged 14 to 18. With previous data from over 165 adult subjects and an expected completion of the last patient visit in Q3 2023, successful trial outcomes could bolster the company's position in the diabetes management market. Senseonics emphasizes the device's unique benefits, allowing pediatric users to remove transmitters during activities, enhancing their quality of life while managing diabetes.
Senseonics Holdings, Inc. (NYSE American: SENS) has granted equity awards to 13 new non-executive employees under its 2019 Inducement Plan. On April 4, 2023, the Compensation Committee approved non-qualified stock options for 200,000 shares and restricted stock units for 250,000 shares, with an exercise price of $0.5951 per share. The options and units will vest over time, contingent on continuous employment. Senseonics focuses on developing innovative long-term implantable glucose monitoring systems aimed at improving diabetes management.
Senseonics Holdings, Inc. (SENS) reported financial results for Q4 and full year 2022, revealing a total revenue of $16.4 million for 2022, up from $13.7 million in 2021. Notably, Q4 2022 revenue reached $5.6 million, marking a rise from $4.0 million in Q4 2021. Gross profit for the full year was $2.7 million, a significant improvement from a gross loss of $0.8 million. The company achieved a net income of $142.1 million in 2022, compared to a net loss of $302.5 million the previous year. Senseonics also anticipates revenue growth for 2023, projecting a range of $20 million to $24 million, indicating an increase of 22% to 46% compared to 2022.
Senseonics (AMEX:SENS) will release its fourth quarter and full year 2022 financial results after market close on March 15, 2023. A joint virtual event with PHC Holdings and Ascensia Diabetes Care will take place on the same day at 6:30 pm ET, featuring presentations from executives including Tim Goodnow and Rick Sullivan. They will discuss the Eversense technology portfolio, commercial partnerships, and provide financial guidance. The webcast will be accessible on Senseonics' website under “Investor Relations” for future reference.